Dec 30, 2025 • openPR.com
NEUTRAL
U.S. Transthyretin Amyloidosis Treatment Market Insights
The U.S. transthyretin amyloidosis treatment market is projected to grow from USD 65.4 million in 2025 to USD 124.4 million by 2032, exhibiting a CAGR of 9.6%. This growth is driven by increasing demand, expanding applications, and technological advancements, with key players like Alnylam Pharmaceuticals Inc. and Pfizer Inc. leading the market. The report provides a comprehensive analysis of market dynamics, competitive landscape, and strategic opportunities for stakeholders.
Dec 27, 2025 • MarketBeat
SOMEWHAT-BULLISH
Highland Capital Management LLC Buys Shares of 4,569 Alnylam Pharmaceuticals, Inc. $ALNY
Highland Capital Management LLC has acquired 4,569 shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, a new position valued at approximately $2.083 million. Institutional ownership of ALNY is high at 92.97%, with significant stakes held by major investors. Insider activity shows net selling recently, while analysts maintain a "Moderate Buy" consensus with an average price target of $477.44.
Dec 23, 2025 • Simply Wall Street
BULLISH
Alnylam Pharmaceuticals (ALNY) Valuation Check After NASDAQ-100 Entry and $250m Manufacturing Expansion
Alnylam Pharmaceuticals (ALNY) recently joined the NASDAQ 100, reflecting its strong performance with a significant share price increase and a five-year total shareholder return above 200%. Despite trading near record highs, the company appears undervalued, with one narrative suggesting a 17.2% undervaluation and a DCF model indicating a 51.5% discount to a fair value of $841 per share. The inclusion and R&D progress, alongside a $250 million manufacturing expansion, position Alnylam as a key player in the RNAi therapy market, though sustained R&D spending and reliance on its TTR franchise present risks.
Dec 23, 2025 • Simply Wall Street
BULLISH
Alnylam Pharmaceuticals (ALNY) Valuation Check After NASDAQ-100 Entry and $250m Manufacturing Expansion
Alnylam Pharmaceuticals (ALNY) recently entered the NASDAQ-100 and announced a $250 million manufacturing expansion, following a strong share price performance and significant R&D progress. While the stock trades near record highs, various valuation models suggest it might still be undervalued. Investors are faced with the dilemma of whether this represents a fresh entry point or if future growth is already priced in.
Dec 23, 2025 • ts2.tech
SOMEWHAT-BULLISH
Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)
Alnylam Pharmaceuticals (ALNY) made its debut on the Nasdaq-100 on December 22, 2025, a significant mechanical event influencing near-term stock flows. The article details ALNY's Monday close and after-hours trading, alongside other recent company developments like a $250 million manufacturing expansion, board changes, and a partial repurchase of convertible notes. Investors are focused on the impact of the Nasdaq-100 inclusion, the company's strong commercial growth, pipeline ambitions, and analyst forecasts ahead of Tuesday's market open in a holiday-shortened week.
Dec 22, 2025 • ts2.tech
BULLISH
Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook
Alnylam Pharmaceuticals (ALNY) has officially joined the Nasdaq-100 Index, a move expected to boost market visibility and institutional ownership. This inclusion follows a strong year driven by the commercial success of its drug AMVUTTRA, robust financial performance in Q3 2025, and a raised revenue outlook for the year. The article also highlights strategic investments in manufacturing expansion, global approvals, and advancements in drug delivery technology, alongside analyst price targets and potential risks.